source
- Altimmune's GLP-1/glucagon shot reduces drinking in Phase 2 alcohol use disorder trialAltimmune announced results from its mid‑stage Phase 2 RECLAIM trial evaluating pemvidutide, a GLP‑1/glucagon dual agonist, in patients with moderate‑to‑severe alcohol use disorder. The trial comp…
- FDA advisory panel debates allowing compounding pharmacies to produce seven peptidesThe FDA’s advisory committee spent two days reviewing whether compounding pharmacies should be permitted to manufacture a set of seven peptide products. The discussion involved both committee membe…